Revelation Biosciences, Inc. (REVB) P/E Ratio History
Historical price-to-earnings valuation from 2023 to 2023
Loading P/E history...
REVB Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 10, 2026, Revelation Biosciences, Inc. (REVB) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.96 and trailing twelve-month earnings per share of $-4.85.
The current P/E is 101% below its 5-year average of 5.9x. Over the past five years, REVB's P/E has ranged from a low of 5.9x to a high of 5.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 21.9x, REVB trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, REVB trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our REVB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
REVB P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 13.6 | - | -26% | |
| $8B | 25.0 | 1.09Best | -25% | |
| $2B | 4.0Lowest | - | +307%Best | |
| $167M | 9.9 | - | +150% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
REVB Historical P/E Data (2023–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $2884.04 | $489.58 | 5.9x | +0% |
Average P/E for displayed period: 5.9x
See REVB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs REVB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare REVB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonREVB — Frequently Asked Questions
Quick answers to the most common questions about buying REVB stock.
Is REVB stock overvalued or undervalued?
REVB current P/E: -0.0x. 5-year average P/E: 5.9x. Percentile: N/A.
How does REVB's valuation compare to peers?
Revelation Biosciences, Inc. P/E of -0.0x compares to sector median of 21.9x. Sector comparison provides relative valuation context.
What is REVB's PEG ratio?
REVB PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2023-2023.